Bringing the Oncology Community Together
Head & Neck Cancers
Dacomitinib Shows Promise in Head and Neck Cancer
Dacomitinib holds promise for the treatment of metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN).
Read More >>
Docetaxel May Cause Intoxication, FDA Warns
FDA Approves Lymphoseek for Head and Neck Cancer
Lenvatinib Likely to Become Standard in Resistant Differentiated Thyroid Cancer
Study Supports Dialing Back Radiation for Some Patients With HPV-Positive Oropharyngeal Cancer
Vokes Charts a New Course in Head and Neck Cancer Treatment
Doxepin Rinse Relieves Pain in Patients With Radiation-Related Oral Mucositis
View More >>
- A Network of Your Peers
View more >>
Evolving Head and Neck Cancer Treatment Landscape
Determining Treatment for RAI-Refractory Thyroid Cancer
Dr. Wirth Discusses the Safety Profile of Lenvatinib as Seen in the SELECT Trial
Most Popular Right Now
Tweets by @OncLive
Medullary Thyroid Cancer: Advances and Challenges
Moderated by Ezra Cohen, MD, this panel discussion includes expert perspectives from Eric J. Sherman, MD, Steven I. Sherman, MD, R. Michael Tuttle, MD, and Lori J. Wirth, MD.
8th Annual Multidisciplinary Symposium on Head and Neck Cancer: Medical Crossfire
CME activity worth 2.0 CME credits led by James Tate Thigpen, MD.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
666 Plainsboro Road
Plainsboro, NJ 08536
Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.